Novel Markers of Pancreatic Adenocarcinoma in Fine-Needle Aspiration: Mesothelin and Prostate Stem Cell Antigen Labeling Increases Accuracy in Cytologically Borderline Cases
Authors:
- Denis M. McCarthyDMDenis M. McCarthy
- Anirban MaitraAMAnirban Maitra
- Pedram ArganiPAPedram Argani
- Anne E. RaderARAnne E. Rader
- Douglas O. FaigelDFDouglas O. Faigel
- N. Tjarda van HeekNHN. Tjarda van Heek
- Ralph H. HrubanRHRalph H. Hruban
- Robb E. WilentzRWRobb E. Wilentz
- 1 September 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 11 (3) , 238-243
Abstract
The interpretation of pancreas fine-needle aspiration (FNA) is extremely difficult given the cytologic overlap of neoplastic and reactive processes. Using serial analysis of gene expression, we have discovered 2 new markers of pancreatic adenocarcinoma, mesothelin and prostate stem cell antigen (PSCA), and confirmed their specificity by immunohistochemical labeling. Here we evaluate the potential contribution of immunohistochemical labeling of mesothelin and PSCA to the interpretation of pancreas FNAs. Thirty pancreas FNAs with follow-up data were reviewed. Unstained cell block sections from these aspirates labeled for mesothelin and PSCA using immunohistochemistry were compared with initial cytologic diagnoses and with follow-up diagnoses. On follow-up, 19 patients proved to have cancer, and 11 did not. Initial cytologic diagnosis of malignancy correlated with carcinoma on follow-up in 12 of 12 cases, and initial benign cytologic diagnosis correlated with benign follow-up in 8 of 9 cases (sensitivity, 92%; specificity, 100%). Six of the 9 patients with suspicious cytology were found to have a carcinoma on follow-up. PSCA labeling was present in 16 of the 19 patients who ultimately were proven to have carcinoma; PSCA labeling was absent in 10 of the 11 lesions proven to be benign (sensitivity, 84%; specificity, 91%). Mesothelin labeling was present in 13 of the 19 patients who ultimately were proven to have carcinoma; mesothelin labeling was absent in 10 of the 11 lesions proven to be benign (sensitivity, 68%; specificity, 91%). Five of the 6 cytologically suspicious cases with malignant follow-up labeled for either PSCA or mesothelin (83%), and 2 of the 6 cases labeled for both markers. None of the 3 suspicious cases with benign follow-up labeled for either PSCA or mesothelin. Increasingly, molecular techniques are identifying potential cancer markers that may have diagnostic utility. In this study, immunohistochemical labeling for 2 of these markers, PSCA and mesothelin, appears highly specific for pancreatic adenocarcinoma in FNA specimens and useful in categorizing cytologically suspicious lesions.Keywords
This publication has 25 references indexed in Scilit:
- K-ras,p53, andDPC4(MAD4) Alterations in Fine-Needle Aspirates of the PancreasAmerican Journal of Clinical Pathology, 2002
- Discovery of Novel Tumor Markers of Pancreatic Cancer using Global Gene Expression TechnologyThe American Journal of Pathology, 2002
- Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancerOncogene, 2000
- Analysis of K‐ras oncogene mutation directly applied to atypical cell clusters on cytologic smear slides of bile and pancreatic juicePathology International, 1998
- Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancersNature Genetics, 1996
- DPC4 , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1Science, 1996
- Molecular Cloning and Expression of Megakaryocyte Potentiating Factor cDNAJournal of Biological Chemistry, 1995
- Detection of P53 protein in cytological specimens of pancreatic diseases obtained by selective endoscopic brushingGastroenterology, 1995
- Molecular markers for diagnostic cytology of neoplasms in the head region of the pancreas: mutation of K-ras and overexpression of the p53 protein product.Journal of Clinical Pathology, 1995
- Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesotheliumInternational Journal of Cancer, 1992